Navigation Links
PharmAthene Reports First Quarter 2009 Financial and Operational Results
Date:5/15/2009

partially offset by reduced travel and other administrative overhead costs.

For the first quarter of 2009 PharmAthene's net loss attributable to common shareholders was $6.0 million or $0.23 per share, compared to $4.7 million or $0.22 per share in the same period of 2008.

PharmAthene's available cash, cash equivalents and short term investments at March 31, 2009 totaled $24.0 million, which excludes restricted cash totaling $9.0 million. For the period ended December 31, 2008, the Company's available cash, cash equivalents and short term investments were $22.9 million, excluding restricted cash of $12.0 million. The increase in cash, cash equivalents and short-term investments at March 31, 2009 from December 31, 2008 is primarily attributable to the receipt of approximately $5.0 million in net proceeds from the public offering of common stock and warrants completed in March 2009, partially offset by funding of operations and the repayment of debt.

David P. Wright, President and Chief Executive Officer of PharmAthene, noted, "The first quarter of 2009 was a productive one for PharmAthene. In addition, we have recently met with senior officials at the Biomedical Advanced Research and Development Authority (BARDA) to discuss the pending FDA submission of our comprehensive regulatory strategy for SparVax(TM) under the recently amended RFP. We submitted a copy of the plan to BARDA last week for review. BARDA officials indicated a willingness to review our proposal when received and we remain on target to meet our stated goal of submitting our plan to FDA by May 21, 2009."

Mr. Wright continued, "BARDA has recently assumed responsibility for funding and oversight of activities under our previous contract for the development of SparVax(TM) with the National Institute of Allergy and Infectious Diseases (NIAID). The scope of work under the BARDA contract, which took effect April 1, 2009, will cover
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
9. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
10. PharmAthene to Delay Release of Full Year 2007 Financial Results
11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... California (PRWEB) August 27, 2014 ... (LLNL), through Lawrence Livermore National Security LLC ... to develop and deliver a state-of-the-art laser system ... facility (ELI Beamlines), under construction in the Czech ... performance, the laser system, called the " High ...
(Date:8/27/2014)... is how plants survive impact by the huge ... while using this energy for photosynthesis. The hypothesis ... blades quickly dissipate the energy throughout the entire ... DTU Physics have now managed to successfully ,film, ... contain light-absorbing proteins which play a role in ...
(Date:8/27/2014)... , Aug. 27, 2014 ... the "Global Lactic Acid  (Biodegradable Polymer, Food ... Trends & Forecasts to 2019" report to ... simplest hydroxyl-carboxylic acid with an asymmetrical carbon atom. ... the biodegradable polymer, food and beverage, personal care ...
(Date:8/27/2014)... “We are honored to be named ... Thangaraj, CEO of Radiant Sage. “We are offering truly ... imaging corelab market to a different level. We ... to efficiently and effectively manage the massive amounts of ... analyzed and read by trained physicians. Being recognized by ...
Breaking Biology Technology:LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3DTU researchers film protein quake for the first time 2Global Lactic Acid (Biodegradable Polymer, Food & Beverage, Personal Care & Pharmaceutical) Market - Trends & Forecasts to 2019 2Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2
... improved IT infrastructure and enterprise plan for Wisconsin ... efficiency, according to presenters at the second annual ... the Monona Terrace. , ,Discussion focused on how ... increase access to broadband networks, educational services, and ...
... University of Wisconsin-Madison announced on Friday that it will be ... research. R. Timothy Mulcahy, a professor of pharmacology and associate ... become vice president of research at the University of Minnesota ... Martin Cadwallader said in a statement. He has been a ...
... recently saw the sudden death of another star. In this ... also not his birthplace. Unfortunately, few were around to sing ... last few weeks of the sudden death of biotech scientist ... in September of this year. An Argentine by birth, Frydman ...
Cached Biology Technology:Wisconsin introduces new state IT plan 2Wisconsin introduces new state IT plan 3Wisconsin introduces new state IT plan 4UW-Madison associate dean, active in stem cells, leaves 2An Argentine biotechman in Wisconsin 2An Argentine biotechman in Wisconsin 3An Argentine biotechman in Wisconsin 4
(Date:8/27/2014)... FREMONT, Calif. , Aug. 27, 2014  WaferGen ... completed its previously announced underwritten public offering of units ... $10,000 per unit for gross proceeds of $20 million, ... expenses payable by the Company.  The shares and warrants ... Each unit sold in the offering consists ...
(Date:8/27/2014)... researchers have identified a gene that could help scientists ... protein in the cell membrane of plants that senses ... conservation machinery accordingly. , "It,s similar to a ... at Duke. , The findings, which appear Aug. ... it easier to feed the world,s growing population in ...
(Date:8/27/2014)... manipulating neural circuits in the brain of mice, ... memories. The research, led by Howard Hughes Medical ... of Technology (MIT), reveals that the connections between ... information about an experience and the part of ... that experience are malleable. , Altering those ...
Breaking Biology News(10 mins):WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3Water 'thermostat' could help engineer drought-resistant crops 2Researchers change the emotional association of memories 2Researchers change the emotional association of memories 3Researchers change the emotional association of memories 4
... QS-21A, a medicinally important molecule that helps the body ... University of Illinois at Urbana-Champaign. , In clinical trials, ... immune response in vaccine therapies against aggressive diseases such ... HIV-1 and malaria. An extract from the bark of ...
... have shown that a commonly used procedure to remove ... does not improve patient outcomes. , The procedure, called ... angioplasty in vein grafts and stenting in carotid arteries. ... the Journal of the American Medical Association, found that ...
... cells, the immune system's sentinels, patrol the labyrinthine blood ... tissue damage and demonstrate a dogged behavior not seen ... show that NKT cells crawl along vessel walls, even ... receive a chemical signal to unleash an immune-system assault ...
Cached Biology News:Columbia study shows widely used artery clearing device does not help patients during heart attack 2Natural Killers Could Lead to New Hepatitis Treatments 2Natural Killers Could Lead to New Hepatitis Treatments 3Natural Killers Could Lead to New Hepatitis Treatments 4
The DNA DipStick Kit is ideal for estimating nucleic acid concentrations and approximate yields. Works with ss- and ds-DNA, RNA, and oligonucleotides at concentrations as low as 0.1 ng/l....
Tris-Hepes kit of BG-163 & BG-165 (order number BG-166)...
... Immunogen: Synthetic peptide derived from ... WNT1 protein. Specificity: Reacts with ... Reactivity: Human Mouse (positive controls: ... cell lysates and mouse Mouse-1 cell ...
... The new StrepMAB-Immo coated microplates can ... immobilization of SerAla-Strep-tag II fusion proteins for ... Also small amounts of such proteins are ... (see graphic on the left) and will ...
Biology Products: